A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorImmunome, Inc.
About this trial
IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.
Eligibility criteria
Qualifiers
Informed consent signed by the participant prior to conducting study-specific procedures
≥18 years of age
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Mantle cell lymphoma (MCL)
Disqualifiers
Previously treated with an ADC with a topoisomerase-1 inhibitor payload, except: Participants with triple negative breast cancer may have received up to one prior ADC with a topoisomerase-1 inhibitor payload.
Previously received a ROR1-targeted therapy (eg, ADC, cell therapy, or monoclonal antibody).
History of an anaphylactic reaction to irinotecan or ≥ grade 3 GI toxicity to prior irinotecan.
Life expectancy < 12 weeks.
Trial design
Treatments tested in this trial
- IM-1021
Treatment groups
117 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov